Package Leaflet: Information for the User
Hexyon Injectable Suspension
Vaccine against diphtheria, tetanus, pertussis (acellular component), hepatitis B (rADN), poliomyelitis (inactivated), and Haemophilus influenzaetype b conjugate (adsorbed)
Read all of this leaflet carefully before your child is vaccinated because it contains important information.
Contents of the package leaflet
Hexyon (DtaP-IPV-HB-Hib) is a vaccine used to protect against infectious diseases.
Hexyon helps protect against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and serious diseases caused by Haemophilus influenzaetype b. Hexyon is administered to children from 6 weeks of age.
The vaccine works by making the body produce its own protection (antibodies) against the bacteria and viruses that cause these different infections:
Important information about the protection provided
In order to ensure that Hexyon is suitable for your child, it is important that you inform your doctor or nurse if your child has any of the following characteristics. If there is anything you do not understand, consult your doctor, pharmacist, or nurse.
Do not use Hexyon if your child:
Warnings and precautions
Before vaccination, consult your doctor, pharmacist, or nurse if your child:
Use of Hexyon with other vaccines or medicines
Tell your doctor or nurse if your child is using, has recently used, or might use any other medicine or vaccine.
Hexyon can be administered at the same time as other vaccines such as pneumococcal vaccines, measles-mumps-rubella vaccines, varicella vaccines, rotavirus vaccines, or meningococcal vaccines.
When administered at the same time as other vaccines, Hexyon should be administered at a different injection site.
Fainting can occur after, or even before, any injection with a needle. Therefore, inform your doctor or nurse if your child has fainted with a previous injection.
Hexyon contains phenylalanine, potassium, and sodium
Hexyon contains 85 micrograms of phenylalanine per 0.5 ml dose. Phenylalanine may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body cannot eliminate it properly.
Hexyon contains less than 1 mmol of potassium (39 mg) and less than 1 mmol of sodium (23 mg) per dose, i.e., it is essentially "potassium-free" and "sodium-free".
Hexyon will be administered to your child by a doctor or nurse who is properly trained in the use of vaccines and equipped to respond to any rare, severe allergic reaction that may occur after injection (see section 4 "Possible side effects").
Hexyon is administered by injection into a muscle (intramuscularly, IM) in the upper leg or arm of your child. The vaccine should never be administered into a blood vessel or under the skin.
The recommended dose is as follows:
Primary vaccination cycle (primary vaccination)
Your child will receive two injections administered at an interval of two months or three injections administered at an interval of one to two months (at least four weeks apart). This vaccine should be used according to the local vaccination schedule.
Additional injections (booster vaccination)
After the primary vaccination cycle, your child will receive a booster dose, according to local recommendations, at least 6 months after the last dose of the primary vaccination cycle. Your doctor will advise on when this dose should be administered.
If your child misses a dose of Hexyon
If your child misses a scheduled injection, it is important that you inform your doctor or nurse. They will decide when the missed dose should be administered.
It is important to follow the doctor's or nurse's instructions to ensure your child completes the vaccination cycle. Otherwise, your child may not be fully protected against the diseases.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this vaccine can cause side effects, although not everybody gets them.
Severe allergic reactions (anaphylactic reaction)
If any of the following symptoms occur after leaving the place where your child received the injection, you should consult a doctor IMMEDIATELY:
When these signs and symptoms (signs or symptoms of an anaphylactic reaction) occur, they usually develop rapidly after administration of the injection and while the child is still in the clinic or doctor's office.
The possibility of severe allergic reactions occurring after receiving this vaccine is rare (may affect up to 1 in 1,000 people).
Other side effects
If your child experiences any of the following side effects, consult your doctor, nurse, or pharmacist.
Possible side effects
Other side effects have been reported occasionally with other vaccines that contain diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, or Hib, and not directly with Hexyon:
Reporting of side effects
If your child experiences any side effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of the month stated.
Store in a refrigerator (between 2 °C and 8 °C).
Do not freeze.
Keep the container in the outer carton to protect it from light.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Hexyon
The active principles per dose (0.5 ml)1 are: | |
Diphtheria toxoid | not less than 20 UI2,4 (30 Lf) |
Tetanus toxoid | not less than 40 UI3,4 (10 Lf) |
Bordetella pertussisantigens | |
Pertussis toxoid | 25 micrograms |
Filamentous hemagglutinin | 25 micrograms |
Inactivated poliovirus5 | |
Type 1 (Mahoney) | 29 antigen units D6 |
Type 2 (MEF-1) | 7 antigen units D6 |
Type 3 (Saukett) | 26 antigen units D6 |
Hepatitis B virus surface antigen7 | 10 micrograms |
Haemophilus influenzaetype b polysaccharide (polyribosylribitol phosphate) | 12 micrograms |
conjugated with tetanus protein | 22-36 micrograms |
1Adsorbed on hydrated aluminum hydroxide (0.6mg Al3+)
2As lower confidence limit (p=0.95) and not less than 30 UI as mean value
3As lower confidence limit (p=0.95)
4Or equivalent activity as determined by immunogenicity assessment
5Grown in Vero cells
6These antigen quantities are strictly the same as those previously expressed as 40-8-32 antigen units D, for virus types 1, 2, and 3 respectively, when measured by another suitable immunochemical method
7Produced in Hansenula polymorpha yeast cells using recombinant DNA technology
The other components are:
Disodium hydrogen phosphate, potassium dihydrogen phosphate, trometamol, sucrose, essential amino acids including L-phenylalanine, sodium hydroxide and/or acetic acid and/or hydrochloric acid (for pH adjustment) and water for injectable preparations.
The vaccine may contain traces of glutaraldehyde, formaldehyde, neomycin, streptomycin, and polymyxin B.
Appearance of the Product and Container Contents
Hexyon is supplied as an injectable suspension in a vial (0.5 ml).
Hexyon is available in packs of 10 vials.
After shaking, the normal appearance of the vaccine is a turbid white suspension.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
Sanofi Winthrop Industrie, 82 Avenue Raspail, 94250 Gentilly, France
Manufacturer:
Sanofi Winthrop Industrie, 1541 avenue Marcel Mérieux, 69280 Marcy l'Etoile, France
Sanofi Winthrop Industrie, Voie de L’Institut - Parc Industriel d'Incarville, B.P 101, 27100 Val de Reuil, France
For further information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:
België/Belgique /Belgien Sanofi Belgium Tel: +32 2 710.54.00 | Lietuva Swixx Biopharma UAB Tel: +370 5 236 91 40 |
Luxembourg/Luxemburg Sanofi Belgium Tel: +32 2 710.54.00 | |
Ceská republika Sanofi, s.r.o. Tel: +420 233 086 111 | Magyarország SANOFI-AVENTIS Zrt Tel: +36 1 505 0055 |
Danmark Sanofi A/S Tel: +45 4516 7000 | MaltaSanofi S.r.l.Tel: +39 02 39394 275 |
Deutschland Sanofi-Aventis Deutschland GmbH Tel: 0800 54 54 010 Tel. from abroad: +49 69 305 21 130 | Nederland Sanofi B.V. Tel: +31 20 245 4000 |
Eesti Swixx Biopharma OÜ Tel: +372 640 10 30 | Norge Sanofi-aventis Norge AS Tel: + 47 67 10 71 00 |
Ελλ?δα ΒΙΑΝΕΞ Α.Ε. Τηλ.: +30.210.8009111 | Österreich Sanofi-Aventis GmbH Tel: +43 (1) 80185-0 |
España sanofi-aventis, S.A. Tel: +34 93 485 94 00 | Polska Sanofi sp. z o. o. Tel: +48 22 280 00 00 |
France Sanofi Winthrop Industrie Tel: 0 800 222 555 Call from abroad: +33 1 57 63 23 23 | Portugal Sanofi – Produtos Farmacêuticos, Lda. Tel: + 351 21 35 89 400 |
Hrvatska Swixx Biopharma d.o.o. Tel: +385 1 2078 500 | România Sanofi Romania SRL Tel: +40 21 317 31 36 |
Ireland sanofi-aventis Ireland T/A SANOFI Tel: + 353 (0) 1 4035 600 | Slovenija Swixx Biopharma d.o.o Tel: +386 235 51 00 |
Ísland Vistor Tel: +354 535 7000 | Slovenská republika Swixx Biopharma s.r.o. Tel: +421 2 208 33 600 |
Italia Sanofi S.r.l. Tel: 800536389 | Suomi/Finland Sanofi Oy Tel: +358 (0) 201 200 300 |
Κ?προς C.A. Papaellinas Ltd. Τηλ.: +357 22 741741 | Sverige Sanofi AB Tel: +46 8-634 50 00 |
Latvija Swixx Biopharma SIA Tel: +371 6 6164 750 | United Kingdom (Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2525 |
Date of Last Revision of this Leaflet
Other Sources of Information
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.
The most recent approved information on this vaccine is available at the following URL: https://hexyon.info.sanofi or by scanning the QR code with your mobile phone (smartphone):
[QR code to be included]
--------------------------------------------------------------------------------------------------------------------
This information is intended for healthcare professionals only:
Disposal of unused medicinal products and all materials that have come into contact with them should be done in accordance with local regulations.